Curr Cardiol Rev. 2020 Dec 10. doi: 10.2174/1573403X16999201210200614. Online ahead of print.
In December 2019, a novel COVID-19 caused by SARS-CoV-2 has emerged as a global emergency. In a few months, the pathogen has infected millions of people in the world. Primarily SARS-CoV-2 infects the pulmonary system which ultimately leads to ARDS and lung failure. The majority of patients develop milder symptoms but the infection turns severe in a huge number of people which ultimately results in enhanced mortality in COVID-19 patients. Co-morbid conditions primarily cardiovascular complications and diabetes have been reported to show a strong correlation with COVID-19 severity. Further, the onset of myocardial injury secondary to pulmonary damage has been observed in critically ill patients who have never reported heart-related ailments before. Due to drastic health risks associated with virus infection, the unprecedented disruption in normal business throughout the world has caused an economic misery. Apparently, newer treatments are urgently needed to combat the virus particularly to reduce the severity burden. Therefore, understanding the cross-talk between lung and heart during COVID-19 might give us better clarity for early-diagnosis followed by appropriate treatment in patients with the likelihood of developing severe symptoms. Accordingly, the present review highlights the potential mechanisms that may explain the cross-talk between lung and heart so that effective treatment/management strategies can be evolved swiftly in this direction.